Skip to main content
Top
Published in: Internal and Emergency Medicine 2/2018

01-03-2018 | IM - ORIGINAL

Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey

Authors: Chao-Feng Chang, Yu-Chen Tseng, Hsin-Hung Huang, Yu-Lueng Shih, Tsai-Yuan Hsieh, Hsuan-Hwai Lin

Published in: Internal and Emergency Medicine | Issue 2/2018

Login to get access

Abstract

Pancreatic cancer is difficult to diagnose in an early stage, and has the highest mortality of all types of cancer. Obesity, high body mass index, and increased abdominal girth are established risk factors. Some studies have postulated that there is a correlation between organ steatosis and pancreatic cancer. This study aims to explore whether nonalcoholic fatty liver disease (NAFLD) is a risk factor and a prognostic factor for pancreatic cancer. The study enrolled 557 patients (143 with and 414 without pancreatic cancer) who were diagnosed between January 2009 and December 2013. We reviewed the abdominal computed tomographic scans of the patients to confirm the diagnosis of NAFLD. Clinical parameters, laboratory data, and personal information were analyzed. NAFLD is an independent risk factor for pancreatic cancer according to adjusted multivariate logistic regression analysis (OR 2.63, 95% CI 1.24–5.58, p = 0.011). The Kaplan–Meier survival curve reveals that patients without NAFLD have longer survival than patients with NAFLD (p = 0.005, log-rank test). NAFLD is positively correlated with pancreatic cancer, a result suggesting that NAFLD may increase the incidence and risk of pancreatic cancer. Patients with pancreatic cancer and NAFLD have poorer overall survival than patients without NAFLD, perhaps, because dysregulated cytokine status leads to progression of pancreatic cancer. NAFLD may be a prognostic factor for pancreatic cancer.
Literature
1.
2.
go back to reference Lowenfels AB, Maisonneuve P (2004) Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34(5):238–244CrossRefPubMed Lowenfels AB, Maisonneuve P (2004) Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34(5):238–244CrossRefPubMed
3.
go back to reference Shaib Y, Davila J, El-Serag H (2006) The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24(1):87–94CrossRefPubMed Shaib Y, Davila J, El-Serag H (2006) The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24(1):87–94CrossRefPubMed
5.
go back to reference Food N (2007) Physical activity, and the prevention of cancer: a global perspective. Washington, DC Food N (2007) Physical activity, and the prevention of cancer: a global perspective. Washington, DC
7.
go back to reference Włodarek D, Jerzy Podleśny JS (2007) Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Roczniki Państwowego Zakładu 58(1):129 Włodarek D, Jerzy Podleśny JS (2007) Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Roczniki Państwowego Zakładu 58(1):129
8.
go back to reference Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56(4):952–964CrossRefPubMed Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56(4):952–964CrossRefPubMed
9.
go back to reference Machado M, Cortez-Pinto H (2006) Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 9(5):637–642CrossRefPubMed Machado M, Cortez-Pinto H (2006) Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 9(5):637–642CrossRefPubMed
11.
go back to reference Targher G, Rossi A, Zamboni G, Fantin F, Antonioli A, Corzato F et al (2012) Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J Endocrinol Investig 35(8):748 Targher G, Rossi A, Zamboni G, Fantin F, Antonioli A, Corzato F et al (2012) Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J Endocrinol Investig 35(8):748
12.
go back to reference Smits MM, van Geenen EJ (2011) The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 8(3):169–177CrossRefPubMed Smits MM, van Geenen EJ (2011) The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 8(3):169–177CrossRefPubMed
13.
go back to reference Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R et al (2009) Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg 208(5):989–994CrossRefPubMed Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R et al (2009) Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg 208(5):989–994CrossRefPubMed
14.
go back to reference Sanna C, Rosso C, Marietti M, Bugianesi E (2016) Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci 17(5):717CrossRefPubMedCentral Sanna C, Rosso C, Marietti M, Bugianesi E (2016) Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci 17(5):717CrossRefPubMedCentral
15.
go back to reference Saba L, di Martino M, Bosco S, del Monte M, de Cecco CN, Lombardo V et al (2015) MDCT classification of steatotic liver: a multicentric analysis. Eur J Gastroenterol Hepatol 27(3):290–297CrossRefPubMed Saba L, di Martino M, Bosco S, del Monte M, de Cecco CN, Lombardo V et al (2015) MDCT classification of steatotic liver: a multicentric analysis. Eur J Gastroenterol Hepatol 27(3):290–297CrossRefPubMed
16.
go back to reference Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ et al (2010) Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 194(3):623–628CrossRefPubMed Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ et al (2010) Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 194(3):623–628CrossRefPubMed
17.
go back to reference Park YS, Park SH, Lee SS, Kim DY, Shin YM, Lee W et al (2011) Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology 258(3):760–766CrossRefPubMed Park YS, Park SH, Lee SS, Kim DY, Shin YM, Lee W et al (2011) Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology 258(3):760–766CrossRefPubMed
18.
go back to reference Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML et al (2009) Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553–2562CrossRefPubMedPubMedCentral Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML et al (2009) Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553–2562CrossRefPubMedPubMedCentral
19.
go back to reference Balentine CJ, Enriquez J, Fisher W, Hodges S, Bansal V, Sansgiry S et al (2010) Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg 14(11):1832–1837CrossRefPubMed Balentine CJ, Enriquez J, Fisher W, Hodges S, Bansal V, Sansgiry S et al (2010) Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg 14(11):1832–1837CrossRefPubMed
20.
go back to reference McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, De Andrade M et al (2010) Obesity adversely affects survival in pancreatic cancer patients. Cancer 116(21):5054–5062CrossRefPubMedPubMedCentral McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, De Andrade M et al (2010) Obesity adversely affects survival in pancreatic cancer patients. Cancer 116(21):5054–5062CrossRefPubMedPubMedCentral
21.
go back to reference Olson SH, Chou JF, Ludwig E, O’Reilly E, Allen PJ, Jarnagin WR et al (2010) Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer 127(10):2412–2419CrossRefPubMed Olson SH, Chou JF, Ludwig E, O’Reilly E, Allen PJ, Jarnagin WR et al (2010) Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer 127(10):2412–2419CrossRefPubMed
23.
go back to reference De González AB, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjær J et al (2006) Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 15(5):879–885CrossRefPubMed De González AB, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjær J et al (2006) Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 15(5):879–885CrossRefPubMed
24.
go back to reference van Geenen E-JM, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ (2010) Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 39(8):1185–1190CrossRefPubMed van Geenen E-JM, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ (2010) Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 39(8):1185–1190CrossRefPubMed
25.
go back to reference Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A (2016) Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 11(1):3–10CrossRefPubMed Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A (2016) Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 11(1):3–10CrossRefPubMed
26.
go back to reference Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22(4):625–638CrossRefPubMed Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22(4):625–638CrossRefPubMed
27.
go back to reference Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472–1489CrossRefPubMed Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472–1489CrossRefPubMed
28.
go back to reference Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W, Kasuga M (2002) Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 24(1):42–46CrossRefPubMed Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W, Kasuga M (2002) Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 24(1):42–46CrossRefPubMed
29.
go back to reference Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M (1995) Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55(10):2007–2011PubMed Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M (1995) Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55(10):2007–2011PubMed
30.
go back to reference Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN (2008) FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29(6):1096–1107CrossRefPubMedPubMedCentral Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN (2008) FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29(6):1096–1107CrossRefPubMedPubMedCentral
31.
go back to reference Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T (2010) Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 16(15):1854–1858CrossRefPubMedPubMedCentral Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T (2010) Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 16(15):1854–1858CrossRefPubMedPubMedCentral
35.
go back to reference Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD et al (2003) Regulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163(3):1001–1011CrossRefPubMedPubMedCentral Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD et al (2003) Regulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163(3):1001–1011CrossRefPubMedPubMedCentral
36.
go back to reference Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D (2003) Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302(1):46–55CrossRefPubMed Zeng H, Datta K, Neid M, Li J, Parangi S, Mukhopadhyay D (2003) Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302(1):46–55CrossRefPubMed
37.
go back to reference Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J et al (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294(22):2872–2878CrossRefPubMed Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J et al (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294(22):2872–2878CrossRefPubMed
38.
go back to reference Iodice S, Gandini S, Maisonneuve P, Lowenfels AB (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393(4):535–545CrossRefPubMed Iodice S, Gandini S, Maisonneuve P, Lowenfels AB (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393(4):535–545CrossRefPubMed
39.
go back to reference Nakamura K, Nagata C, Wada K, Tamai Y, Tsuji M, Takatsuka N et al (2011) Cigarette smoking and other lifestyle factors in relation to the risk of pancreatic cancer death: a prospective cohort study in Japan. Jpn J Clin Oncol 41(2):225–231CrossRefPubMed Nakamura K, Nagata C, Wada K, Tamai Y, Tsuji M, Takatsuka N et al (2011) Cigarette smoking and other lifestyle factors in relation to the risk of pancreatic cancer death: a prospective cohort study in Japan. Jpn J Clin Oncol 41(2):225–231CrossRefPubMed
40.
go back to reference Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar H-J (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394CrossRefPubMed Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar H-J (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394CrossRefPubMed
41.
go back to reference Blais L, Desgagné A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160(15):2363–2368CrossRefPubMed Blais L, Desgagné A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160(15):2363–2368CrossRefPubMed
42.
go back to reference Simon MS, Desai P, Wallace R, Wu C, Howard BV, Martin LW et al (2016) Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. Cancer Causes Control 27(3):415–423CrossRefPubMed Simon MS, Desai P, Wallace R, Wu C, Howard BV, Martin LW et al (2016) Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. Cancer Causes Control 27(3):415–423CrossRefPubMed
43.
go back to reference Shimoyama S (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 67(4):729–739CrossRefPubMed Shimoyama S (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 67(4):729–739CrossRefPubMed
44.
go back to reference Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9(5):259–267CrossRefPubMed Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9(5):259–267CrossRefPubMed
45.
go back to reference Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59(17):4356–4362PubMed Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59(17):4356–4362PubMed
46.
go back to reference Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ (2004) Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96(7):524–528CrossRefPubMed Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ (2004) Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96(7):524–528CrossRefPubMed
47.
go back to reference Zhang Y-P, Wan Y-D, Sun Y-L, Li J (2015) Zhu R-T. A meta-analysis of observational studies. Sci Rep, Aspirin might reduce the incidence of pancreatic cancer, p 5 Zhang Y-P, Wan Y-D, Sun Y-L, Li J (2015) Zhu R-T. A meta-analysis of observational studies. Sci Rep, Aspirin might reduce the incidence of pancreatic cancer, p 5
Metadata
Title
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey
Authors
Chao-Feng Chang
Yu-Chen Tseng
Hsin-Hung Huang
Yu-Lueng Shih
Tsai-Yuan Hsieh
Hsuan-Hwai Lin
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 2/2018
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-017-1774-x

Other articles of this Issue 2/2018

Internal and Emergency Medicine 2/2018 Go to the issue

Acknowledgement to Referees

Reviewers 2017

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.